Competitor Analysis: Erythropoiesis Stimulating Agents (ESA)

Erythropoiesis Stimulating Agents (ESA)

Product description

The Competitive Intelligence Report Erythropoiesis Stimulating Agents (ESA) as of April 2013 provides information on existing first and second generation epoetin products in regulated markets, an overview on biosimilar versions of erythropoietin (EPO) in regulated markets, a compilation of novel, next generation Erythropoiesis Stimulating Agents (ESAs) separately for biologics and for oral small molecules and a summary of first generation EPO products as well as of darbepoietin biosimilar versions in less regulated markets.

Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently marketed Erythropoieitin (EPO) & Erythropoiesis Stimulating Agents (ESA) products and active EPO and ESA projects in research and development. In addition, the report lists company-specific product portfolios and R&D pipelines of Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) on the market or in R&D. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.